Mat Pilates and Vascular Function in Obese Females
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03907384 |
|
Recruitment Status :
Completed
First Posted : April 9, 2019
Last Update Posted : October 30, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obese Elevated Blood Pressure | Behavioral: Mat Pilates training | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 28 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Effects of Mat Pilates Training on Vascular Function in Obese Premenopausal Women With Elevated Blood Pressure |
| Actual Study Start Date : | April 1, 2018 |
| Actual Primary Completion Date : | October 30, 2018 |
| Actual Study Completion Date : | October 30, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Mat Pilates training
The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
|
Behavioral: Mat Pilates training
This group completed 12-weeks of training |
|
No Intervention: Control
Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
|
- Arterial Stiffness [ Time Frame: 12 weeks ]via Pulse Wave Velocity
- Systolic and Diastolic Blood Pressure [ Time Frame: 12 weeks ]Automatic BP monitor
- Pressure Wave Reflection [ Time Frame: 12 weeks ]via Augmentation Index
- Endothelial Function [ Time Frame: 12 weeks ]via plasma nitric oxide
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- body mass index 30-40 kg/m2
- <1 h of regular exercise per week in the previous year
- systolic/diastolic BP: 120-129mm Hg systolic BP and ˂ 80 mm Hg for diastolic BP
- Nonsmokers
Exclusion Criteria:
- body mass index ˂30 and ≥40 kg/m2
- chronic diseases
- taking oral contraceptives
- pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03907384
| United States, Nebraska | |
| University of Nebraska | |
| Omaha, Nebraska, United States, 68022 | |
| Responsible Party: | Alexei Wong, Assistant Professor, Marymount University |
| ClinicalTrials.gov Identifier: | NCT03907384 |
| Other Study ID Numbers: |
1342019 |
| First Posted: | April 9, 2019 Key Record Dates |
| Last Update Posted: | October 30, 2020 |
| Last Verified: | October 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Hypertension Vascular Diseases Cardiovascular Diseases |

